ArticleBritish journal of cancer2025
Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trial
- Multimodal data-based graph convolutional networks for predicting outcomes in ovarian cancer receiving neoadjuvant chemotherapy.NPJ precision oncology · 2026Article
- Integrative Genomic and Functional Analysis Reveals NF1 Loss as a Modifier of DNA Damage and Replication Stress Responses in Ovarian Cancer.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResidual disease (RD) following cytoreductive surgery is prognostic for epithelial ovarian cancer (EOC) patients. Few studies have evaluated RD and survival by tumor histotype and across continuous RD diameter.
methods2608 individuals with stages III-IV invasive EOC diagnosed between 2013 and 2022 were identified using the Cancer Registry of Norway. In flexible parametric models, we compared excess mortality comparing RD versus no macroscopic residual disease (NMRD); systemic anti-cancer therapy was evaluated in a sub-cohort from 2019. Excess mortality was assessed across continuous RD size using restricted cubic splines.
resultsAmong 1849 patients with cytoreductive surgery, survival was worse for individuals with RD (vs. NMRD), excess hazard ratio (EHR) = 2.62 (95% confidence interval = (2.27-3.01)); no heterogeneity was observed by histotype (p = 0.21). Patients with 0.1-0.4 cm RD had 2-fold higher risk of death (EHR = 2.09 (1.63-2.68)) relative to women with NMRD; ~3-fold higher risk was observed for all other categories (e.g., 0.5-0.9 cm, EHR = 2.97 (2.26-3.89); 3.0-20 cm, 2.75 (2.05-3.70)). No significant difference in three-year survival was observed across continuous RD diameter (p ≥ 0.17). NMRD was associated with better survival regardless of neoadjuvant chemotherapy. DISCUSSION: Achieving NMRD resulted in the best survival outcomes. Among patients with RD, we observed no significant difference in survival by RD diameter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.